Precision Nanomedicine in Cardiothoracic Oncology: Overcoming the Clinical Paradox of Cisplatin through Supramolecular and Stimuli-Responsive Engineering

Cisplatin remains a foundational standard for treating solid thoracic malignancies, particularly non-small cell lung cancer (NSCLC). However, its clinical utility is continually constrained by a profound “clinical paradox” in which exceptional cytotoxic potency is offset by a dangerously narrow therapeutic index. From a cardiothoracic surgical perspective, dose-limiting nephrotoxicity represents a direct obstacle that may prematurely close the “optimal surgical window” by depleting a patient’s physiological reserve. This review evaluates advanced drug delivery systems (DDS)—specifically cyclodextrin-complexed liposomes and stimuli-responsive nanovesicles—as essential tools for navigating biological bottlenecks, such as intracellular thiol sequestration and transport downregulation. Molecular engineering strategies, including sheddable polyethylene glycol (PEG) shields and zwitterionic coatings, are examined for their potential to bypass accelerated blood clearance (ABC) and immune recognition. Furthermore, the integration of green nanotechnology and theranostic imaging for real-time intraoperative monitoring is highlighted, ena-bling clinicians to titrate fluid management and vasopressor support with enhanced precision. By utilizing precision platforms such as NC-6004 (Nanoplatin), which achieves a maximum tolerated dose of 135 mg/m²—nearly double the standard regimen—with superior tolerability, clinicians can facilitate “surgical reclaimability” for previously unfit patients. Ultimately, these nanomedi-cines decouple systemic toxicity from oncological efficacy, ensuring patients maintain the physiological integrity necessary for survival during high-stakes thoracic procedures.